פרסומים - ד"ר אבי טרבס
Avi Treves - List of Publications
1. Stavy L, Treves AJ, Feldman M. Effect of concanavalin A on lymphocyte-mediated cytotoxicity. Nature. 1971 Jul 2; 232(5305):56-8.
2. Stavy L, Treves AJ, Feldman M. Capacity of thymic cells to effect target cell lysis following treatment with concanavalin A. Cell Immunol. 1972 Apr; 3(4):623-8.
3. Treves AJ, Cohen IR. Recruitment of effector T lymphocytes against a tumor allograft by T lymphocytes sensitized in vitro. J Natl Cancer Inst. 1973 Dec; 51(6):1919-25.
4. Cohen IR, Treves AJ. Recruitment of effector lymphocytes in autosensitization and transplantation reactions. Proc. 8th Leucocyte Culture Conference, Academic Press, New York, pp. 4:722-727, 1974.
5. Treves AJ, Carnaud C, Trainin N, Feldman M, Cohen IR. Enhancing T lymphocytes from tumor-bearing mice suppress host resistance to a syngeneic tumor. Eur J Immunol. 1974 Nov; 4(11):722-7.
6. Treves AJ, Cohen IR, Feldman M. Immunotherapy of lethal metastases by lymphocytes sensitized against tumor cells in vitro. J Natl Cancer Inst. 1975 Mar; 54(3):777-80.
7. Schechter B, Treves AJ, Feldman M. Proceedings: in vitro destruction of 3LL tumor cells by syngeneic in vitro-sensitized lymphocytes. Isr J Med Sci. 1975 Dec; 11(12):1396-7.
8. Treves AJ, Cohen IR, Feldman M. Immunotherapy of tumor metastases by in vitro sensitized lymphocytes. Trans. Proc. 7:529-530, 1975.
9. Treves AJ, Cohen IR, Feldman M, Weiss DW. Effect of treatment with the methanol extraction residue fraction of killed tubercle bacilli (MER) on the development of spontaneous pulmonary metastases from syngeneic implants of tumor 3LL in C57B1 mice. Isr J Med Sci. 1976 Apr-May; 12(4-5):384-7.
10. Schechter B, Treves AJ, Feldman M. Specific cytotoxicity in vitro of lymphocytes sensitized in culture against tumor cells. J Natl Cancer Inst. 1976 May; 56(5):975-9.
11. Treves AJ, Cohen IR, Feldman M. In vivo effects of lymphocytes sensitized in vitro. In: Corynebacterium Parvum. B. Halpern, ed., Plenum Press, pp. 107-111, 1976.
12. Manor Y, Treves AJ, Cohen IR, Feldman M. Transition from T cell protection to T cell enhancement during tumor growth in an allogeneic host.Transplantation. 1976 Oct; 22(4):360-6.
13. Treves AJ, Schechter B, Cohen IR, Feldman M. Sensitization of T lymphocytes in vitro by syngeneic macrophages fed with tumor antigens. J Immunol. 1976 Apr; 116(4):1059-64.
14. Treves AJ, Cohen IR, Feldman M. Suppressor factor secreted by T-lymphocytes from tumor-bearing mice. J Natl Cancer Inst. 1976 Aug; 57(2):409-14.
15. Treves AJ, Cohen IR, Schechter B, Feldman M. In vivo effects of lymphocytes sensitized in vitro against tumor cells. Ann N Y Acad Sci. 1976; 276:165-75.
16. Treves AJ, Feldman M, Kaplan HS. Primary cultures of human spleen macrophages in vitro. J Immunol Methods. 1976; 13(3-4):279-87.
17. Treves AJ, Feldman M, Kaplan HS. Macrophage-mediated in vitro sensitization of T-lymphocytes: I. Detection of murine leukemia virus-associated antigens. J Natl Cancer Inst. 1977 May; 58(5):1527-9.
18. Treves AJ, Feldman M, Kaplan HS. In vitro sensitization of human lymphocytes against histiocytic lymphoma cell lines. I. Primary sensitization of lymphocyte subpopulations. J Immunol. 1977 Sep; 119(3):955-60.
19. Treves AJ, Honsik C, Liebrman M, Decleve A, Feldman M, Kaplan HS. In vitro sensitization of lymphocytes Against murine viral associated antigens by antigen-fed macrophages. Econoprint, pp. 108-117, 1977.
20. Treves AJ, Declève A, Lieberman M, Feldman M, Kaplan HS. Macrophage-mediated in vitro sensitization of lymphocytes. II. The detection of neo-antigens on transformed lymphocytes and passages of normal fibroblasts. J Immunol. 1978 Jun; 120(6):1947-51.
21. Treves AJ, Heidelberger E, Feldman M, Kaplan HS. In vitro sensitization of human lymphocytes against histiocytic lymphoma cell lines. II. Characterization of two different effector activities and of suppressor cells. J Immunol. 1978 Jul; 121(1):86-90.
22. Treves AJ, Heidelberger E, Feldman M, Kaplan HS. In vitro sensitization of human lymphocytes against allogeneic cells by antigen-fed macrophages. Isr J Med Sci. 1979 Jul; 15(7):564-9.
23. Treves AJ, Heidelberger E, Kaplan HS. In vitro sensitization of human lymphocytes against histiocytic lymphoma cell lines. III. The activity of culture-induced suppressor cells. J Immunol. 1979 Feb; 122(2):643-7.
24. Treves, A.J., Honsik, C., Feldman, M. and Kaplan. H.S Macrophage mediated in vitro sensitization of lymphocytes. III influence on growth of a transplanted murine lymphoma. Cancer Immunol. Immunother. 6:179-184, 1979.
25. Miller RA, Treves AJ, Kaplan HS. Cytotoxic T-lymphocyte and spontaneous killer cell activity against human T- and B-lymphoid cell lines. Cell Immunol. 1979 Sep 15; 47(1):46-56.
26. Treves AJ, Feldman M, Honsik C, Kaplan HS. In vivo activity of lymphocytes sensitized in vitro by antigen-fed macrophages: inhibition of lymphoma growth. Adv Exp Med Biol. 1979; 114:629-34.
27. Treves AJ, Barak V, Fuks Z. In vitro proliferation of macrophage depleted human peripheral blood lymphocytes. Clin Exp Immunol. 1979 Dec; 38(3):531-8.
28. Rachmilewitz D, Ligumski M, Treves AJ, Tal T, Zor U, Sharon P, Karmeli P.Prostaglandis in clonic Inflammation In: The International Colloquium in Gastroenterology. H.D. Yanowitz & D.B. Sacher Eds., pp. 347-3111 1979.
29. Rachmilewitz EA, Treves A, Treves AJ. Susceptibility of thalassemic red blood cells to phagocytosis by human macrophages in vitro. Ann N Y Acad Sci. 1980; 344:314-22.
30. Treves AJ, Yagoda D, Haimovitz A, Ramu N, Rachmilewitz D, Fuks Z. The isolation and purification of human peripheral blood monocytes in cell suspension. J Immunol Methods. 1980; 39(1-2):71-80.
31. Treves AJ, Barak V, Fuks Z. Characterization of human lymphocytes which proliferate "spontaneously" in vitro. Eur J Immunol. 1980 Nov; 10(11):883-7.
32. Treves AJ, Horowitz A, Biran S, Brufman G, Fuks Z. Comparison of the response to PHA and suppressor macrophage function in different age groups of cancer patients and healthy controls. Cancer. 1981 Dec 15; 48(12):2606-11.
33. Treves AJ, Tal T, Barak V, Fuks Z. Antigen presentation and regulatory functions of human monocytes in the in vitro response of lymphocytes against purified protein derivative of tuberculin (PPD). Eur J Immunol. 1981 Jun; 11(6):487-92.
34. Haimovitz A, Fuks Z, Galili N, Treves AJ. Changes in peanut agglutinin binding to human monocytes during their maturation to macrophages. J Reticuloendothel Soc. 1982 Mar; 31(3):187-92.
35. Rachmilewitz D, Ligumsky M, Haimovitz A, Treves AJ. Prostanoid synthesis by cultured peripheral blood mononuclear cells in inflammatory diseases of the bowel. Gastroenterology. 1982 Apr; 82(4):673-9.
36. Treves AJ, Ligumski M, Fuks Z, Haimovitz A, Rachmilewitz D. Prostaglandin E2 secretion by subsets of human peripheral blood monocytes. Immunopharmacology. 1982 Jun; 4(3):267-76.
37. Treves AJ, Haimovitz A, Fuks Z. Changes in surface markers of human monocytes following their in vitro maturation to macrophages. Adv Exp Med Biol. 1982; 155:227-32.
38. Carroll J, Fuks Z, Catane R, Fridkin M, Treves AJ. The effect of tuftsin on human monocyte cytotoxicity. J Biol Response Modifiers 1:245-252, 1982.
39. Horowitz AT, Fuks Z, Okon E, Biran S, Treves AJ. The use of carcinoembryonic antigen for identification of human tumor cells in malignant effusions. Oncology. 1983; 40(1):18-25.
40. Zifroni A, Treves AJ, Sachar DB, Rachmilewitz D. Prostanoid synthesis by cultured intestinal epithelial and mononuclear cells in inflammatory bowel disease. Gut. 1983 Jul; 24(7):659-64.
41. Treves AJ, Barak V, Tal T, Fuks Z. Constitutive secretion of interleukin 1 by human monocytes. Eur J Immunol. 1983 Aug; 13(8):647-51.
42. Haimovitz A, Fuks Z, Rubenstein M, Treves AJ. The instability of membrane markers expressed by human monocytes and macrophages in culture. Immunobiology. 1983 Dec; 165(5):432-44.
43. Barak V, Fuks Z, Galilli N, Treves AJ. Selection and continuous growth of antigen-specific human T cells by antigen-treated monocytes. Eur J Immunol. 1983 Nov; 13(11):952-6.
44. Treves AJ, Fuks Z, Voss R, Tal T, Barak V, Konijn AM, Kaplan R, Laskov R.Establishment of cell lines from somatic cell hybrids between human monocytes and mouse myeloma cells. J Immunol. 1984 Feb; 132(2):690-4.
45. Laskov R, Fuks Z, Barak V, Treves AJ. Somatic cell hybrids between human monocytes and mouse myeloma cells. Immunology and Hematology Research monograph No. 2:350-354, 1984.
46. Catane R, Pfeffer MR, Livni N, Rosenmann E, Treves AJ, Eshhar Z. Monoclonal antibodies to carcinoembryonic antigen (CEA) in primary and metastatic tumors.Immunology and Hematology Research monograph No. 2:358-361, 1984.
47. Treves AJ, Haimovitz A, Halimi M, Fibach E, Fuks Z. Marker analysis of cloned populations of human monocytes. Exp Hematol. 1985 Feb; 13(2):111-6.
48. Treves AJ, Fibach E, Kaiser N, Weinstein D, Maoz H, Halimi M, Simon A, Rachmilewitz D. Development of macrophage and granulocyte colonies from human peripheral blood. Int J Radiat Oncol Biol Phys. 1985 Feb; 11(2):271-5.
49. Treves AJ, Halperin M, Barak V, Bar-Tana R, Halimi M, Fibach E, Gamliel H, Leizerowitz R, Polliack A. A new myelomonoblastic cell line (M20): analysis of properties, differentiation, and comparison with other established lines of similar origin. Exp Hematol. 1985 May; 13(4):281-8.
50. Horowitz AT, Treves AJ, Voss R, Okon E, Fuks Z, Davidson L, Biran S. A new human ovarian carcinoma cell line: establishment and analysis of tumor-associated markers. Oncology. 1985; 42(5):332-7.
51. Maoz H, Kaiser N, Halimi M, Barak V, Haimovitz A, Weinstein D, Simon A, Yagel S, Biran S, Treves AJ. The effect of estradiol on human myelomonocytic cells. 1. Enhancement of colony formation. J Reprod Immunol. 1985 Jun; 7(4):325-35.
52. Catane R, Sulkes A, Uziely B, Gez E, Isaacson R, Treves AJ, Fridkin M. Initial clinical studies with Tuftsin. Int J Immuntherapy. 2:81-85, 1986.
53. Maoz H, Polliack A, Barak V, Yatziv S, Biran S, Giloh H, Treves AJ. Parameters affecting the in vitro maturation of human monocytes to macrophages. Int J Cell Cloning. 1986 May; 4(3):167-85.
54. Treves AJ, Barak V, Halperin M, Biran S, Leizerowitz R, Polliack A. In vitro differentiation and establishment of cell lines derived from human myelomonocytic leukemia cells. Immunol Lett. 1986 Apr; 12(4):225-30.
55. Barak V, Biran S, Halimi M, Treves AJ. The effect of estradiol on human myelomonocytic cells. II. Mechanism of enhancing activity of colony formation. J Reprod Immunol. 1986 Dec; 9(4):355-63.
56. Levo Y, Wollner S, Treves AJ. Serum amyloid P-component levels in patients with malignancy. Scand J Immunol. 1986 Aug; 24(2):147-51.
57. Barak V, Yamin M, Braun S, Halperin M, Biran S, Milner Y, Treves AJ.Detection of different interleukin-1 activities in human monocytes and monocytic cell lines. J Biol Response Mod. 1986 Aug; 5(4):362-75.
58. Barak V, Treves AJ, Yanai P, Halperin M, Wasserman D, Biran S, Braun S.Interleukin 1 inhibitory activity secreted by a human myelomonocytic cell line (M20). Eur J Immunol. 1986 Nov; 16(11):1449-52.
59. Gazitt Y, Sammar M, Treves AJ, Manny N, Gurfel D, Polliack A. Generation of a monoclonal anti-GP70 antibody and characterization of its reactivity with various human cell lines and cells from leukemia-lymphoma patients. Immunol Lett. 1986 Mar; 12(2-3):101-8.
60. Barak V, Carlin D, Sulkes A, Treves A, Biran S. CA15-3 serum levels in breast cancer and other malignancies--correlation with clinical course. Isr J Med Sci. 1988 Sep-Oct; 24(9-10):623-7.
61. Polliack A, Leizerowitz R, Barak V, Treves AJ, Gazitt Y. Effects of retinoic acid and phorbol ester on lymphocytes and monocytes in B-lymphocytic leukemia.Isr J Med Sci. 1988 Sep-Oct; 24(9-10):522-32.
62. Barak V, Roisman I, Caroline D, Slkes A, Treves AJ, Many I, Biran S. CA15-3 In breast cancer. BAMAH: J. Health proffesionals in the field of cancer: 5:69-75, 1989.
63. Friedman G, Barak V, Chajek-Shaul T, Etienne J, Treves AJ, Stein O, Stein Y.Recombinant human interleukin-1 suppresses lipoprotein lipase activity, but not expression of lipoprotein lipase mRNA in mesenchymal rat heart cell cultures. Biochim Biophys Acta. 1991 May 2; 1089(1):83-7.
64. Barak V, Peritt D, Flechner I, Yanai P, Halperin T, Treves AJ, Dinarello CA. The specific IL-1 inhibitor from the human M20 cell line is distinct from the IL-1 receptor antagonist. Lymphokine Cytokine Res. 1991 Dec; 10(6):437-42.
65. Mordel N, Anteby SO, Zajicek G, Roisrnan I, Treves AJ, Barak V. CA-125 is present in significant concerntrations in Periovulatory and Sterility. 57: 377-380, 1992.
66. Peled T, Rigel M, Peritt D, Fibach E, Treves AJ, Barak V. Effect of M20 interleukin-1 inhibitor on normal and leukemic human myeloid progenitors.Blood. 1992 Mar 1; 79(5):1172-7.
67. Barak V, Mordel N, Holzer H, Zajicek G, Treves AJ, Laufer N. The correlation of interleukin 1 and tumour necrosis factor to oestradiol, progesterone and testosterone levels in periovulatory follicular fluid of in-vitro fertilization patients. Hum Reprod. 1992 Apr; 7(4):462-4.
68. Barak V, Mordel N, Zajicek G, Kalichman I, Treves AJ, Laufer N. The correlation between interleukin 2 and soluble interleukin 2 receptors to oestradiol, progesterone and testosterone levels in periovulatory follicles of in-vitro fertilization patients. Hum Reprod. 1992 Aug; 7(7):926-9.
69. Barak V, Peritt D, Flechner I, Sherman Y, Okone E, Yanai P, Halperin T, TrevesAJ. The M20 IL-l Inhibitor prevents onset of adjuvant Arthritis. Biotherapy, 4:317-232, 1992.
70. Peritt D, Flechner I, Okunev E, Yanai P, Halperin T, Treves AJ, Barak V. The M20 IL-1 inhibitor. I. Purification by preparative isoelectric focusing in free solution. J Immunol Methods. 1992 Nov 5; 155(2):159-65.
71. Peritt D, Flechner I, Yanai P, Okunev E, Halperin T, Treves AJ, Barak V. The M20 IL-1 inhibitor. II. Biological characterization. J Immunol Methods. 1992 Nov 5; 155(2):167-74.
72. Barak V, Yanai P, Treves AJ, Roisman I, Simon A, Laufer N. Interleukin-1: local production and modulation of human granulosa luteal cells steroidogenesis.Fertil Steril. 1992 Oct; 58(4):719-25.
73. Barak V, Peritt D, Flechner I, Yanai P, Halperin T, Dinarello C, Treves AJ. The IL 1 inhibitor prevents and Reduces in vivo. In: Pathophysiology and Pharmacology of Cytokines, pages 257-263. Biomedical Press 1992.
74. Barak V, Peritt D, Yanai P, Halperin T, Treves AJ. In vivo anti inflammatory effects of the M20 IL-1 inhibitor: I. Effects on acute inflammatory parameters. Biotherapy. 1993; 6(4):263-70.
75. Barak V, Gorodetsky R, Weidenfeld J, Peritt D, Yanai P, Halperin T, Treves AJ.In vivo anti-inflammatory effects of the M20 IL-1 inhibitor: II. Effects on serum reactants. Biotherapy. 1993; 6(4):271-7.
76. Fibach E, Rigel M, Peled T, Treves AJ, Barak V. The effect of human myelomonocytic leukemic cell line (M20) derived IL-1 inhibitor on human erythroid cell development. Leuk Lymphoma. 1994 Oct; 15(3-4):327-32.
77. Peled T, Landau E, Prus E, Treves AJ, Nagler A, Fibach E. Cellular copper content modulates differentiation and self-renewal in cultures of cord blood-derived CD34+ cells. Br J Haematol. 2002 Mar; 116(3):655-61.
78. Besser MJ, Treves AJ, Itzhaki O, Hardan I, Nagler A, Papa MZ, Catane R, Winkler E, Shalmon-Zifroni B, Schachter J. Adoptive cell therapy for metastatic melanoma patients: pre-clinical development at the Sheba Medical Center. Isr Med Assoc J. 2006 8:164-8.
79. Markel G, Seidman R, Stern N, Cohen-Sinai T, Izhaki O, Katz G, Besser M, Treves AJ, Blumberg RS, Loewenthal R, Mandelboim O, Orenstein A, Schachter J.Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions. J Immunol. 2006 177:6062-71
80. Keshet GI, Goldstein I, Yitzhaki O, Cesarkas K, Shenhav L, Yakirevitch A, Treves AJ, Schachter J, Amariglio N, Rechavi G. MDR1 expression identifies human melanoma stem cells. Biochem Biophys Res Commun. 2008 Apr 18; 368(4):930-6
81. Schallmach E, Sareli R, Besser MJ, Leipsiger S, Hardan I, Treves AJ, Nagler A, Schachter J. Collection of Large-scale Expanded Lymphocyte Cultures for Adoptive Immunotherapy Using a COBE Spectra Apheresis Machine.
J Immunother. 2008 31: 563
82. Markel G, Seidman R, Cohen Y, Cohen Sinai T, Treves A.J, Orenstein A, Berger R, Schachter J. Dynamic expression of protective CEACAM1 on melanoma cells during specific immune attack.
Immunology. 2009 Feb;126(2):186-200.
83. Besser MJ, Oved K, Schallmach E, Treves AJ, Reiter Y, Schachter J. Modifying IL-2 Concentrations during Culture Improves Function of T Cells for Adoptive Immunotherapy. Cytotherapy. 2009 11:(2):206-217.
84. Markel G, Choen Sinai T, Besser MJ, Kfir O, Itzhaki O, Seidnan R, Treves AJ, Fridman E, Keisari Y, Dotan Z, Ramon J, Schachter J. Preclinical Evaluation of Adoptive Cell Therapy for Metastatic Renal Cell Carcinoma Patients. Anticancer Res. 2009 Jan; 29(1):145-54.
85. Besser MJ, Shapira R, Treves AJ, Zippel D, Itzhaki O, Schallach E, Kubi A,Shalmon B, Hardan I, Catane R. Segal E, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A. Nagler A, Schachter J. Minimallty – cultured or selected autologous tumer infiltrating lymphocyters following a lymphodepleting chemotherapy Regimen in Metastatic Melanoma Patients J Immunother. 2009 May;32(4):415-23.
86. Markel G, Seidman R, Besser MJ, Zabari N, Ortenberg R, Shapira R, Treves AJ,Loewenthal R, Orenstein A, Nagler A, Schachter J. Natural killer lysis receptor (NKLR)/NKLR-ligand matching as a novel approach for enhancing anti-tumor activity of allogeneic NK cells. PLoS ONE. 2009;4(5):e5597.
87. Markel G, Ortenberg R, Seidman R, Sapoznik S, Koren-Morag N, Besser M, J Bar J, Shapira R, Kubi A, Nardini G, Tessone A, Treves AJ, Winkler E, Orenstein A and Schachter J. Systemic dysregulation of CEACAM1 in the melanoma patients. Cancer Immunol Immunother. 2010 59(2):215-30
88. Besser MJ, Schallmach E, Oved K, Treves AJ, Markel G, Reiter Y, Schachter J.Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy. Cytotherapy. 2009;11(2):206-17.
89. Besser MJ, Shapira R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz l, Levy D,Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G,Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J. Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-Term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients. Clinical Cancer Research 2010 1;16(9):2646-55
90. Itzhaki O, Hovav E, Ziporen Y, Levy D, Kubi A, Zickich D, Hershkovitz L, Treves AJ, Shalmon B, Markel G, Schachter J, Besser MJ. Establishment and large-scale expansion of minimallycultured "Young" Tumor Infiltrating Lymphocytes (TIL) for adoptive transfer therapy. J Immunother2011 34(2):212-20.
91. Zippel DB, Besser M, Shapira R, Ben-Nun A, Goitein D, Davidson T, Treves AJ, Markel G, Schachter J, Papa MZ.
Adoptive cell therapy with autologous tumor-infiltrating lymphocytes and high-dose interleukin-2 for metastatic melanoma: The surgeon's perspective. Exp Ther Med. 2012 3(5):898-902.
92. Itzhaki O, Levy D, Zikich D, Treves AJ, Markel G, Schachter J and Besser MJ. Adoptive T-cell transfer in melanoma. Immunother. 5(1):79-90. 2013
93. Orit Itzhaki1, Eyal Greenberg, Bruria Shalmon, Adva Kubi, Avraham J. Treves, Ronnie Shapira-Frommer1, Camilla Avivi, Rona Ortenberg, Eytan Ben-Ami, Jacob Schachter, Michal J. Besser,Gal Markel, Nicotinamide Inhibits Vasculogenic Mimicry, an Alternative Vascularization Pathway Observed in Highly Aggressive Melanoma PLoS One. 2013;8(2):e57160
94. Adoptive Transfer of Tumor Infiltrating Lymphocytes in Metastatic Melanoma Patients: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies Michal J Besser Ronnie Shapira-Frommer, Orit Itzhaki, Avraham J Treves, Dov Zippel, Daphna Levy, Adva Kubi, Noa Shoshani, Dragoslav Zikich, Yaara Ohayon, Daniel Ohayon, Bruria Shalmon, Gal Markel, Ronit Yerushalmi, Sara Apter, Alon Ben-Nun, Eytan Ben-Ami, Avichai Shimoni, Arnon Nagler, and Jacob Schachter Clin Cancer Res. 19: 4792 2013
95. Transplantation of human bone marrow mesenchymal stem cells as a thin subretinal layer ameliorates retinal degeneration in a rat model ofretinal dystrophy Tzameret A, Sher I, Belkin M, Treves AJ, Meir A, Nagler A,Levkovitch-Verbin H, Barshack I, Rosner M, Rotenstreich Y
Experimental Eye Research 118:135-144 2014
96. Enriching Hematopoietic Endothelial and Mesenchymal Functional Progenitors by Short-Term Culture of Steady-State Peripheral blood Mononuclear Cells Obtained from Healthy Donors and Ischemic Patients Varda-Bloom N, Treves AJ, Kroupnik T, Spiegelstein D, Raanani E,and Nagler A, Isr Med Assoc J. 16:774 2014
Review Articles
1. Treves AJ, Cohen IR, Feldman M. A syngeneic metastatic tumor model in mice: the natural immune response of the host and its manipulation. Isr J Med Sci. 1976 Apr-May; 12(4-5):369-84.
2. Treves AJ. In vitro induction of cell-mediated immunity against tumor cells by antigen-fed macrophages. Immunol Rev. 1978; 40:205-26. Review.
3. Catane R, Schlanger S, Weiss L, Penchas S, Fuks Z, Treves AJ, Gottlieb P, Fridkin M. Toxicology and antitumor activity of tuftsin. Ann N Y Acad Sci. 1983; 419:251-60.
4. Treves AJ. The origin of monocyte-macrophage heterogeneity: possible alternatives. Med Hypotheses. 1984 Aug; 14(4):335-46. Review.
5. Treves AJ. Human monocytes and macrophages: establishment and analysis of cloned populations and functional cell lines. Crit Rev Immunol. 1985; 5(4):371-85. Review.
